Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Designing opioids that deter abuse.

Raffa RB, Pergolizzi JV Jr, Muñiz E, Taylor R Jr, Pergolizzi J.

Pain Res Treat. 2012;2012:282981. doi: 10.1155/2012/282981. Epub 2012 Nov 8.

2.

Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?

Bannwarth B.

Drugs. 2012 Sep 10;72(13):1713-23. doi: 10.2165/11635860-000000000-00000. Review.

PMID:
22931520
3.

Opioid formulations designed to resist/deter abuse.

Raffa RB, Pergolizzi JV Jr.

Drugs. 2010 Sep 10;70(13):1657-75. doi: 10.2165/11537940-000000000-00000. Review.

PMID:
20731474
4.

Update on abuse-resistant and abuse-deterrent approaches to opioid formulations.

Webster L.

Pain Med. 2009 Jul;10 Suppl 2:S124-33. doi: 10.1111/j.1526-4637.2009.00672.x. Review.

5.

Non-analgesic effects of opioids: factors relevant to opioid abuse and abuse- deterrent formulations.

Pergolizzi JV, Raffa RB, Pergolizzi JS, Taylor R.

Curr Pharm Des. 2012;18(37):6109-15. Review.

PMID:
22747546
6.

Opioid formulations in development designed to curtail abuse: who is the target?

Webster LR, Bath B, Medve RA.

Expert Opin Investig Drugs. 2009 Mar;18(3):255-63. doi: 10.1517/13543780902751622 . Review.

PMID:
19243277
7.

Opioids in headache treatment. Is there a role?

Ziegler DK.

Neurol Clin. 1997 Feb;15(1):199-207. Review.

PMID:
9058406
8.

Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?

Schneider JP, Matthews M, Jamison RN.

CNS Drugs. 2010 Oct;24(10):805-10. doi: 10.2165/11584260-000000000-00000. Review.

PMID:
20839893
9.

College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement.

Zacny J, Bigelow G, Compton P, Foley K, Iguchi M, Sannerud C.

Drug Alcohol Depend. 2003 Apr 1;69(3):215-32. Review.

PMID:
12633908
10.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
11.

Abuse-deterrent opioid formulations: are they a pipe dream?

Katz N.

Curr Rheumatol Rep. 2008 Jan;10(1):11-8. Review.

PMID:
18457606
12.

The burden of the nonmedical use of prescription opioid analgesics.

Gilson AM, Kreis PG.

Pain Med. 2009 Jul;10 Suppl 2:S89-100. doi: 10.1111/j.1526-4637.2009.00668.x. Review.

13.

The role of abuse-deterrent formulations in countering opioid misuse and abuse.

Nguyen V, Raffa RB, Taylor R, Pergolizzi JV Jr.

J Clin Pharm Ther. 2015 Dec;40(6):629-34. doi: 10.1111/jcpt.12337. Epub 2015 Nov 23. Review.

PMID:
26595258
14.

Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse.

Sehgal N, Manchikanti L, Smith HS.

Pain Physician. 2012 Jul;15(3 Suppl):ES67-92. Review.

15.

Recent advances in abuse-deterrent technologies for the delivery of opioids.

Maincent J, Zhang F.

Int J Pharm. 2016 Aug 20;510(1):57-72. doi: 10.1016/j.ijpharm.2016.06.012. Epub 2016 Jun 9. Review.

PMID:
27291971
16.

Drug Formulation Advances in Extended-Release Medications for Pain Control.

Jones MR, Carney MJ, Kaye RJ, Prabhakar A, Kaye AD.

Curr Pain Headache Rep. 2016 Jun;20(6):36. doi: 10.1007/s11916-016-0565-9. Review.

PMID:
27084375
17.

What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review.

Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS.

Pain Med. 2008 May-Jun;9(4):444-59. doi: 10.1111/j.1526-4637.2007.00370.x. Review.

18.

Clinical strategies for the primary health care professional to minimize prescription opioid abuse.

Gudin JA.

Postgrad Med. 2012 May;124(3):131-8. doi: 10.3810/pgm.2012.05.2556. Review.

PMID:
22691907
19.

Current approaches in tamper-resistant and abuse-deterrent formulations.

Mastropietro DJ, Omidian H.

Drug Dev Ind Pharm. 2013 May;39(5):611-24. doi: 10.3109/03639045.2012.680468. Epub 2012 Apr 26. Review.

PMID:
22537282
Items per page

Supplemental Content

Write to the Help Desk